Puma Biotechnology | PBYI - Biaya Operasional





Biaya Operasional Perubahan Tanggal
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Daiichi Sankyo JPY 483.8B 5.85B 2026-09
Exelixis USD 390.27M 10M 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
Glaxosmithkline GBP 6.76B 1.42B 2026-09
Incyte USD 5.64B 4.67B 2026-09
MacroGenics USD 42.87M 21.68M 2026-06
Moderna USD 1.18B 223M 2026-09
Novartis USD 9.88B 325M 2026-09
Pfizer USD 89B 3.81B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Takeda JPY 981.78B 36.71B 2026-09
TG Therapeutics USD 218.66M 48.54M 2026-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09